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Abstract: The correct formation of the aortic arch arteries depends on a coordinated and regulated
gene expression profile within the tissues of the pharyngeal arches. Perturbation of the gene regulatory
networks in these tissues results in congenital heart defects affecting the arch arteries and the outflow tract
of the heart. Aberrant development of these structures leads to interruption of the aortic arch and double
outlet right ventricle, abnormalities that are a leading cause of morbidity in 22q11 Deletion Syndrome
(DS) patients. We have recently shown that Pax9 functionally interacts with the 22q11DS gene Tbx1 in the
pharyngeal endoderm for 4th pharyngeal arch artery morphogenesis, with double heterozygous mice
dying at birth with interrupted aortic arch. Mice lacking Pax9 die perinatally with complex cardiovascular
defects and in this study we sought to validate further potential genetic interacting partners of Pax9,
focussing on Gbx2 which is down-regulated in the pharyngeal endoderm of Pax9-null embryos. Here,
we describe the Gbx2-null cardiovascular phenotype and demonstrate a genetic interaction between
Gbx2 and Pax9 in the pharyngeal endoderm during cardiovascular development.
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1. Introduction
Normal morphogenesis of the mammalian heart and aortic arch arteries is controlled by a complex
interaction of tissues and gene expression. Genetic mutations that alter heart development result in
congenital heart defects which affect nearly 1% of the population, and result in structural defects to the
heart and its associated great vessels [1]. Conotruncal defects affecting the outflow tract (OFT) of the
heart and the aortic arch arteries are a major feature in 22q11 deletion syndrome (DS) [2], and of the 45
genes haploinsufficient in these patients, TBX1 is thought to be the most important for cardiovascular
development [3–5]. The OFT is formed from cells of the second heart field (SHF), a group of progenitor
cells located in the splanchnic mesoderm that migrate to the heart and subsequently continue to provide
progenitors to the heart throughout embryogenesis [6]. Initially formed as a common vessel, the OFT
divides into the aorta and pulmonary trunk, and these two vessels separate and rotate around each
other as the aorticopulmonary septal complex spirals caudally. Septation is completed by the fusion
of the interventricular septum with the OFT endocardial cushions of the atrioventricular canal [7]
and requires a contribution from neural crest cells [8]. Failure in the fusion of the OFT cushions,
or if the OFT rotates aberrantly, can result in common arterial trunk (CAT) and transposition of the
great arteries (TGA), respectively [9]. An atrioventricular septal defect (AVSD) can occur if there is
an abnormal fusion of the superior and inferior endocardial cushions [10]. The aortic arch arteries
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are derived from the pharyngeal arch arteries (PAAs) that form within the pharyngeal arches from
SHF-derived endothelial cells [11]. The pharyngeal arches are a transient series of protrusions that
develop in a cranial to caudal sequence along the lateral surface of the head [12] and are comprised
of endoderm, mesoderm, ectoderm, and neural crest cell-derived mesenchyme [13]. The pharyngeal
arches develop by forming pouches from the endoderm that meet clefts from the ectoderm to define
the boundaries of each arch [14] and the endoderm is considered vital for providing cues for this
patterning event in a range of species [15–17]. Disruption to pharyngeal segmentation is seen when
pharyngeal endoderm gene expression is perturbed [15,18–20]. There are five bilaterally symmetrical
pairs of PAAs that connect the aortic sac to the dorsal aorta. The PAAs then asymmetrically remodel
to form the left-sided aortic arch and double circulatory system [21] and this process is conserved
between mice and humans [22]. Aberrant PAA formation and remodelling can result in defects such as
interruption of the aortic arch type B (IAA-B) [23].
The 22q11DS gene Tbx1 is known to interact with many genes in cardiovascular development,
including Pax9 [24,25] and Gbx2 [24]. Pax9 is specifically expressed in the pharyngeal endoderm at
embryonic day (E) 9.5 [26], although it is later expressed in the craniofacial region and skeleton.
Mice deficient for Pax9 die perinatally with a cleft palate, absent pharyngeal-derived glands,
skeletal abnormalities and have complex heart and aortic arch artery defects [25,27]. Pax9 has
been shown to functionally interact with Tbx1 in the pharyngeal endoderm for 4th PAA morphogenesis,
as double-heterozygous mice develop IAA-B [25]. Gbx2 has also been implicated in cardiovascular
development [28,29] and is normally expressed in all three germ layers of the mouse at the early head
fold stage (E7.5) in a domain that extends rostrally from the posterior end of the embryo, encompassing
the node, into the prospective hindbrain [30]. In the pharynx, Gbx2 is expressed in the pharyngeal
arch endoderm and ectoderm at E8.5 [31] but restricted to the pharyngeal endoderm by E9.5 [28].
Gbx2 is downregulated in the pharyngeal endoderm of Pax9-null embryos [25] and in the pharyngeal
endoderm and ectoderm of Tbx1-null embryos [28].
In this study, we have examined the cardiovascular phenotype in Gbx2-null mice and identified a
genetic interaction for cardiovascular development between Gbx2 and Pax9 in complex mutants in the
pharyngeal endoderm. We also explored a potential genetic interaction between Tbx1, Pax9 and Gbx2
for aortic arch artery morphogenesis.
2. Materials and Methods
2.1. Mice
The mice used in this study have previously been described: Gbx2flox [32], Pax9+/− [27], Pax9Cre [25],
Sox2Cre [33], Tbx1+/− [34], and R26ReYFP [35]. All mice were maintained on a C57Bl/6J genetic background.
All studies involving animals were performed in accordance with the UK Home Office Animals
(Scientific Procedures) Act 1986.
2.2. Breeding
Male and female mice were mated and the detection of a vaginal plug the next morning considered
to be embryonic day (E) 0.5. Pregnant females were culled on the required day and embryos collected.
Embryos at E9.5–E11.5 were staged by somite counting. PCR genotyping primers are available
on request.
2.3. Imaging
Magnetic resonance imaging (MRI), High Resolution Episcopic Microscopy (HREM) and
micro-computed tomography (µCT) techniques were performed as previously described [25,36–39].
Volume data sets were segmented using Amira software (ThermoFisher Scientific, Waltham, MA, USA)
to create 3-dimensional (3-D) images. Structures were manually outlined using the label field function
of Amira and surface rendered to produce the 3-D images. Intra-cardiac ink injections were performed
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as described [28]. Haematoxylin and eosin staining, immunohistochemistry, and whole-mount in
situ hybridisation, were performed using standard techniques. mRNA expression on sections was
examined by in situ hybridisation using RNAscope® Multiplex Fluorescent v2 Assay (Advanced Cell
Diagnostics, Newark, CA, USA) following the manufacturer’s instructions. Probe and antibody details
are given in Table S5.
2.4. Identifying Conserved Binding Sites in the GBX2 Locus
Human and mouse genomic GBX2 sequences were aligned in Geneious 10.2.6 (https://www.
geneious.com) using the Align feature, identifying a highly conserved region ~2kb downstream from
the 2nd and final GBX2 coding exon. This region was scanned for TBX1/5 and PAX5/9 consensus
binding sequences using the rVista (https://rvista.dcode.org/) and JASPAR (http://jaspar.genereg.net/)
databases. One TBX5 and three PAX5/9 sites were identified with the following sequences: TBX-BE-1,
CAGCACCTCA; PAX-BE-1, AGGCAGCCCTTGATG; PAX-BE-2, GTCTCAGCTGGCTGATTAA; and
PAX-BE-3, TTAATCCAAGGTTGGGTTTTG.
2.5. Luciferase Assay
The 500 bp Gbx2 conserved region was amplified from mouse genomic DNA by PCR and
sub-cloned into the pGL3-Promoter plasmid (Promega, Madison, WI, USA) downstream of luciferase.
The cDNAs for PAX9 and TBX1 were cloned into pcDNA3.1. JEG3 cells were seeded at a density of
1 × 105 cells per well in 24-well plates and transfections were performed in triplicate with jetPRIME
(Polyplus-transfection, Illkirch, France) using a total of 0.5 µg DNA in a reaction volume of 300 µL.
Positive control reporter constructs were 2xTkGl2, containing synthetic TBX binding sites [5],
and p2.4BMP4-luc which binds PAX9 [40]. A renilla luciferase vector (5 ng) was included as a
transfection control. Wells without DNA or with the empty pcDNA3.1 vector served as negative
controls. All wells received an equal quantity of DNA per transfection. A dual-luciferase assay
(Promega) was performed 24 h after transfection.
2.6. Flow Cytometry
The pharyngeal arch region of E9.5 Pax9Cre;eYFP control embryos (n = 5; 23–27 somites) was
dissected from the rest of the embryo and dissociated to single cells with Accumax (ThermoFisher
Scientific) by incubating at 37 ◦C for 30 min. The reaction was stopped by the addition of 10% fetal calf
serum (FCS), the cells washed in PBS, and resuspended in 10% FCS. Cells were stained with propidium
iodide. Fluorescence-activated cell sorting was performed on a Becton Dickinson FACS Aria II using a
100 µm nozzle and a sheath pressure of 20 psi. Single cells were gated using FSC-A vs SSC-A followed
by FSC-A vs. FSC-H and FSC-A vs SSC-W to remove any doublets. Live single cells were gated using
propidium iodide vs. FSC-A, and this population finally gated on eYFP-positive and -negative cells
and sorted into collection tubes.
2.7. Quantitative Real-Time RT-PCR (qPCR)
RNA from flow-sorted cells was extracted using Trizol reagent (ThermoFisher Scientific) combined
with a Purelink RNA Mini Kit (ThermoFisher Scientific) and on-column DNase1 treatment. RNA was
eluted with 30 µL RNase-free water. Total RNA was converted to cDNA using a High-Capacity cDNA
Reverse transcription kit (Applied Biosystems) and random hexamers. qPCR was performed using
SYBR Green JumpStart Taq ReadyMix (Sigma, St. Louis, MO, USA) using previously described Gbx2
and Gapdh primers [25]. All qPCR reactions were performed in triplicate on a QuantStudio 7 Real-Time
PCR System (ThermoFisher Scientific). Data were analysed using the comparative Ct method.
2.8. Statistical Analysis
A chi-squared test was used to compare genotype frequencies of litters. Fisher’s exact test
and Pearson chi-squared test for associations were used to compare defect frequencies between the
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different genotypes (SPSS). qPCR data were tested for variance using the Shapiro–Wilk test (Prism 8.01
software, GraphPad) and a two-tailed unpaired t-test performed. Luciferase data were analysed using
one-way ANOVA with Tukey’s multiple comparison test (Prism 8.01 software, GraphPad). Groups
were considered significantly different when p < 0.05.
3. Results
3.1. Gbx2 Expression in the Pharyngeal Endoderm
Coordinated gene expression in the pharyngeal arches is a prerequisite for the correct development
of the PAA. We confirmed the expression of Gbx2, Pax9 and Tbx1 in mid-embryogenesis mouse embryos.
At E8.5, Gbx2 and Pax9 are expressed in the pharyngeal region of the mouse embryo, with Gbx2
also expressed at the mid-hindbrain boundary (Figure 1A,B) [27,28,41]. At E9.5, Gbx2 and Pax9 are
co-expressed in the pharyngeal endoderm (Figure 1C), as are Pax9 and Tbx1 (Figure 1D) [25]. Gbx2, Pax9
and Tbx1 expression are maintained in the pharyngeal endoderm at E10.5 (Figure 1E,F). Analysis of
Pax9Cre activated eYFP positive cells [25] by qPCR from E9.5 embryos confirmed that Gbx2 expression
is enriched in the pharyngeal endoderm compared to the remaining pharyngeal arch tissues (Figure 1G).
Gbx2 expression is bilaterally reduced in the pharyngeal endoderm of Pax9-null embryos at E9.5 as
shown by whole-mount in situ hybridisation (Figure 1H–K) [25].
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also expressed in the mid-hindbrain (mhb) (n = 3 embryos per probe, 9–11 somites). (C–F) RNAScope
probes were used on sections at E9.5 (n = 3, 24–28 somites) and E10.5 (n = 3, 33 somites). At E9.5
Pax9 and Gbx2 (C), and Pax9 and Tbx1 (D) co-localise to the pharyngeal endoderm. At E10.5 Pax9
(E), Gbx2 (E’) and Tbx1 (F), are all expressed in the pharyngeal endoderm. (G) qPCR on flow-sorted
cells from Pax9Cre;eYFP E9.5 embryos (n = 5, 23–27 somites) shows a significant enrichment for Gbx2
in the eYFP-positive cells compared to eYFP-negative. * p < 0.05; two-tailed unpaired t-test. (H,J)
Whole embryo in situ hybridisation at E9.5 in wild-type (H; n = 3, 24–26 somites) and Pax9−/− (J; n = 6,
23–27 somites) embryos. Gbx2 expression is reduced in the pharyngeal pouch in Pax9−/− embryos.
(I,K) Sections of stained embryos revealed reduced Gbx2 staining in the pharyngeal endoderm in
Pax9−/− embryos (K) compared to controls (I). (L) Diagram of the GBX2 locus showing the degree of
conservation (%) between human and mouse GBX2 sequences. A 500 bp region, ~2kb down from
the second, and final, GBX2 coding exon is 99% conserved and contains PAX (blue) and TBX (red)
binding elements (BE). (M–O) Luciferase assays show that Pax9 activates the Gbx2 conserved region but
Tbx1 does not (O). Controls for Tbx1 (M) and Pax9 (N) show significant activation of luciferase. Data
presented as the mean ± s.e.m. of 6 individual experiments, each performed in triplicate. * p < 0.05,
*** p < 0.01, **** p < 0.001. Scale bars: 100 µm in (A,B,H,J); 50 µm in (C–F),(H’, I, J’,K). Abbreviations:
me, mesoderm; pa, pharyngeal arch; pe, pharyngeal endoderm; s, somites. The somite numbers
given in the legend reflect the range analysed for the whole study. The figure contains representative
images only.
We have previously identified Gbx2 as a potential target gene of Pax9 [25]. To examine the Gbx2
locus for potential regulatory elements we aligned the mouse and human sequences and found a 500 bp
region with 99% homology (Figure 1L). This region, located ~2kb downstream of the second and final
Gbx2 coding exon, contains a previously reported TBX binding site [42]. Scanning this region identified
the known TBX site as well as three potential PAX binding sites. This 500 bp conserved region was
sub-cloned into a luciferase plasmid and transfected into JEG3 cells with PAX9 and TBX1 expression
plasmids. Dual-luciferase assays showed a significant upregulation of luciferase in the presence of
the PAX9 expression plasmid, but no effect was seen with TBX1 (Figure 1O). Co-transfection of PAX9
with TBX1 resulted in no increase in luciferase compared to the control suggesting that TBX1 might be
repressing the effect of PAX9 on the Gbx2 conserved region. This data implies that PAX9 and TBX1
may interact with a potential GBX2 enhancer to regulate the expression of GBX2, and this interaction is
likely to occur in the pharyngeal endoderm where all three genes are expressed from E9.5.
3.2. Gbx2-Null Cardiovascular Defects
As Gbx2 was significantly down-regulated in Pax9−/− embryos [25], and PAX9 was able to activate
a conserved region of the Gbx2 locus, we asked whether these two genes genetically interacted in vivo.
Gbx2−/− mice have previously been shown to have cardiovascular defects at foetal and embryonic
stages [28,29]. To confirm these observations we created a null allele of Gbx2 by crossing Gbx2flox
mice [32] with Sox2Cre mice [33], which drives Cre-mediated recombination in all embryonic tissues
by gastrulation. Gbx2flox;Sox2Cre mice, carrying the recombined Gbx2-null allele, hereafter referred to
as the Gbx2− allele, were subsequently crossed with wild-type mice to breed out the Sox2Cre allele and
to propagate the Gbx2− allele through the germline. Heterozygous Gbx2+/− mice were intercrossed
to generate Gbx2−/− embryos for analysis of cardiovascular developmental defects. Slide in situ
hybridisation on E9.5 embryo sections demonstrated complete loss of Gbx2 RNA in Gbx2−/− embryos
(Figure S1). Genotype analysis of embryos and neonates (E8.5 to P0) indicated there was a statistically
significant reduction in the expected number of Gbx2−/− offspring observed (Table S1) despite no
evidence of an excessive number of resorptions.
Analysis of Gbx2−/− embryos at E15.5 by magnetic resonance imaging (MRI) revealed that 64%
(n = 16/25) had some form of cardiovascular developmental defect including aberrant right subclavian
artery (A-RSA), right-sided aortic arch (RAA), right-sided arterial duct (RAD) and double-outlet
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right ventricle (DORV) (Figure 2A–C; Table 1), although interruption of the aortic arch (IAA) was not
observed. Of these Gbx2−/− embryos with cardiovascular defects, 56% (n = 9/16) displayed additional
overt left-right patterning defects such as right pulmonary isomerism, bilateral superior caval veins
draining into a common right atrium (i.e., right atrial isomerism), and mirror-image aortic arch arteries
(Figure 2D–H; Table 1). An enlargement of the right dorsal aorta, compared to the left, was also
noted in two Gbx2−/− embryos analysed by high-resolution episcopic microscopy (HREM), indicating
that these embryos would have developed an aberrant right-sided dorsal aorta by the foetal stage
(Figure 2O,P). A left-right patterning phenotype in Gbx2−/− mice has not previously been reported.
Left-right patterning is established via a Nodal-Pitx2c gene regulated pathway [43] and to investigate
whether the left-right patterning defect was due to altered Pitx2c expression, whole-mount in situ
hybridisation was performed on Gbx2−/− embryos at E8.5 (n = 6). No obvious change in Pitx2c
expression, however, was observed in the left lateral plate mesoderm (Figure 2I,J).
Table 1. Number of cardiovascular defects observed in Gbx2;Pax9 mutant mice.
Genotype n Abnormal VSD AVSD DORV +IVC CAT
RAA/RAD
+/or A-SA a
IAA-B +/−
A-RSA
Absent
CC b L-R Defect
c
Gbx2−/− 25 16(64%)
2
(8%) 0 10 (40%) 0
13
(52%) 0 0
9
(36%)
Gbx2+/−;
Pax9+/− 28
6
(21%) 0 0 0 0
4
(14%)
2
(7%) 0 0
Gbx2−/−;
Pax9+/− 14
14
(100%) *
3
(21%) 0
7
(50%)
1
(7%)
8
(57%)
5 **
(36%)
2
(16%)
6
(43%)
Pax9−/− 9 9(100%)
2
(22%) 0
3
(44%) 0 0
8
(89%)
5
(56%) 0
Gbx2+/−;
Pax9−/− 9
9
(100%)
2
(22%) 0
5
(56%)
2
(22%)
1
(11%)
8
(89%)
6
(67%) 0
Gbx2−/−;
Pax9−/− 2
2
(100%) 0
1
(50%) 0
1
(50%)
1
(50%)
1
(50%)
1
(50%) 0
Gbx2−/flox;
Pax9Cre
14 3(21%) 0 0 0 0
3
(21%) 0
1
(7%) 0
Embryos and neonates were collected from Gbx2+/−;Pax9+/− and Gbx2flox;Pax9Cre crosses. All embryos were analysed
at E13.5-E15.5 by MRI, µCT and histology. Neonates were analysed by dissection at P0: Gbx2+/−;Pax9+/− (n = 12),
Gbx2−/−; Pax9+/− (n = 1), Pax9−/− (n = 2), Gbx2+/−;Pax9−/− (n = 2), and Gbx2−/−;Pax9−/− (n = 1). Results for embryos
and neonates are combined. The outflow tract phenotype was not assessed in neonates. All wild-type (n = 12),
Pax9+/− (n = 8), Gbx2+/− (n = 22), Gbx2+/flox (n = 6), Gbx2−/flox (n = 9) and Pax9Cre (n = 12) control embryos and
neonates assessed were normal. There was a statistically significant increase in the incidence of cardiovascular
defects in total, and IAA-B specifically, in Gbx2−/−;Pax9+/− embryos compared to the Gbx2−/− embryos. * p < 0.05,
** p = 0.01 (Fisher’s exact test). a A-SA refers to a right or left retro-esophageal subclavian artery, cervical origin
of the RSA, or an isolated RSA. One Pax9−/−, three Gbx2−/− and both Gbx2−/−; Pax9−/− embryos had isolated RSA.
b Absent common carotid artery (CC), resulting in the internal and external carotid arteries arising directly from
the main aortic vessels, unilaterally or bilaterally. c L-R defect refers to an overt left-right patterning defect where
embryos show either right pulmonary isomerism, right atrial isomerism or mirror image branching of the aortic arch
arteries. Abbreviations: AoA, aortic arch; A-RSA, aberrant right subclavian artery; A-SA, aberrant subclavian artery
(left or right); AVSD, atrioventricular septal defect; DORV + IVC, double outlet right ventricle with interventricular
communication; IAA-B, interruption of the aortic arch, type B; RAA, right-sided aortic arch; RAD, right-sided
arterial duct; RSA, right subclavian artery; VSD, perimembranous ventricular septal defect.
Analysis of Gbx2−/− embryos at E10.5 by intracardiac ink injection and HREM demonstrated
that the 4th PAA was affected in 71% (n = 12/17) of embryos, being either absent or hypoplastic
(Figure 2K–P; Table 2). Ink injection of Gbx2+/− embryos at E10.5 revealed a low level of unilateral 4th
PAA defects (Table 2). Embryos at E11.5 also showed PAA defects by HREM including absent and
hypoplastic 4th PAAs as well as delayed septation of the OFT compared to stage-matched controls
(Figure 2Q–S). Immunohistochemical staining for ERG1 showed that the endothelium within the 3rd
and 4th pharyngeal arches had formed lumenised PAAs at E10.5 in control embryos (Figure 2T), but in
Gbx2−/− embryos a visibly reduced number of endothelial cells around the 4th PAA, or only isolated
endothelial cells present within the 4th pharyngeal arch, were observed (Figure 2U,V).
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Table 2. Number of pharyngeal arch artery defects observed in Gbx2;Pax9 mutant embryos.
Bilateral Defects
Genotype n PAA Abnormal(%)
Unilateral
Defect
Bilateral
Defect Present Hypo/Int/Abs Absent
Gbx2+/− 44 4 3 (7%) 3 (7%) 0 - - -
Gbx2+/−;
Pax9+/− 63 4 20 (32%) 13 (21%) 7 (11%) - 3 4
Gbx2−/− 17 4 12 (71%) 7 (41%) 5 (29%) - 3 2
Gbx2−/−;
Pax9+/− 7 4 7 (100%) 1 (14%) 6 (86%) * - 2 4
Pax9−/− a 22
1 13 (59%) 1 (5%) 12 (55%) 11 1 -
2 8 (36%) 3 (14%) 5 (23%) 4 1 -
3 17 (77%) 3 (14%) 14 (64%) - 10 4
4 22 (100%) 1 (5%) 21 (95%) - 3 18
Gbx2+/−;
Pax9−/−
6
1 6 (100%) 0 6 (100%) 6 - -
2 2 (33%) 2 (33%) 0 - - -
3 6 (100%) 0 6 (100%) - 1 5
4 6 (100%) 0 6 (100%) - - 6
Gbx2−/−;
Pax9−/− 1 4 1 (100%) 0 1 (100%) - - 1
Gbx2+/flox;
Pax9Cre
19 4 2 (10%) 1 (5%) 1 (5%) - - 1
Gbx2−/flox;
Pax9Cre
14 4 7 (50%) * 5 (36%) 2 (14%) - 1 1
Embryos were collected from Gbx2+/−;Pax9+/− and Gbx2flox;Pax9Cre crosses and assessed for PAA defects by
intracardiac ink injections. Gbx2−/− embryos were also imaged using HREM (E10.5, n = 3 and E11.5, n = 5) to
visualise the PAA. Data are combined. For Pax9−/− and Gbx2+/−;Pax9−/− genotypes each left and right PAA 1–4 was
scored as having a unilateral or bilateral defect, and the bilateral defects categorised as either present, a combination
of hypoplastic, interrupted and/or absent (Hypo/Int/Abs), and bilaterally absent. For all other genotypes ink injection
was performed at E10.5 and only the 4th PAA was scored. All control embryos, Pax9+/− (n = 18), Gbx2+/flox (n = 22)
and Gbx2−/flox (n = 15) were normal. There was a significantly increased incidence of bilateral 4th PAA defects
in Gbx2−/−; Pax9+/− embryos compared to Gbx2−/− embryos, and abnormal 4th PAA defects in Gbx2−/flox; Pax9Cre
embryos compared to Gbx2+/flox; Pax9Cre embryos. * p < 0.05 (Pearson’s Chi-square test for associations). a New
data (n = 2) combined with published data (n = 20) [25].
All mice deficient for Gbx2 die perinatally, and a high proportion of these are with cardiovascular
abnormalities affecting the outflow tract and/or the 4th PAA-derived arteries. In contrast to previously
published data, where 50% of Gbx2-null embryos had a PAA phenotype and 39% of foetuses had
a cardiovascular defect [28,29], we observed a higher penetrance of cardiovascular abnormalities
at embryonic (71%) and foetal (64%) stages. Our Gbx2-null embryos did not present with IAA as
previously described [29]. Gbx2 has been postulated to be a downstream target of Pax9 [25], and here
we also demonstrate that a conserved region in the Gbx2 locus is activated by PAX9.
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E15.5 embryos. (A) Gbx2+/+ control embryo with normal heart and aortic arch arteries. (B,C) In Gbx2–/– 
embryos (n = 25), defects seen include double outlet right ventricle (DORV) with interventricular 
communication (IVC), retro-oesophageal aberrant right subclavian artery (A-RSA), isolated RSA (I-
RSA) and right-sided arterial duct (RAD). (D–H) Left-right patterning defects were observed in a 
Figure 2. Cardiovascular defects in Gbx2−/− embryos. (A–H) 3D reconstructions from MRI datasets of
E15.5 embryos. (A) Gbx2+/+ control embryo with normal heart and aortic arch arteries. (B,C) In Gbx2−/−
embryos (n = 25), defects seen include double outlet right ventricle (DORV) with interventricular
communication (IVC), retro-oesophageal aberrant right subclavian artery (A-RSA), isolated RSA (I-RSA)
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and right-sided arterial duct (RAD). (D–H) Left-right patterning defects were observed in a subset of
Gbx2−/− embryos (n = 9/25). (D) Normal lungs from a control embryo showing cranial (Cr), middle (Mi),
caudal (Ca) and accessory (Ac) lobes of the right lung, and a single lobed left lung (LL). (E) Gbx2−/−
embryo with right pulmonary isomerism. (F) Gbx2−/− embryo heart with mirror image arrangement of
the arch arteries and the ventricles, DORV and an aberrant left subclavian artery (A-LSA). (G,H) Dorsal
view of the heart and the caval veins. (G) Control embryo showing the right superior caval vein (RSCV)
and inferior caval vein (ICV) draining directly into the right atrium (RA) and the left SCV (LSVC)
draining into the RA via the coronary sinus (CS). (H) Gbx2−/− embryo with the right and left SCVs, and
the paired ICV, draining directly into a common atrium (right atrial isomerism). (I,J) Whole-mount
in situ hybridisation with a Pitx2 riboprobe. Pitx2 isoforms were seen in the head mesoderm (HM)
and left lateral plate mesoderm (LLPM) of control (n = 3) and Gbx2−/− (n = 6) embryos. All embryos
were between 9–11 somites. (K–M) Intracardiac ink injection into E10.5 embryos (34–38 somites).
(K) In control embryos (n = 18), PAAs 3–6 are patent to ink, are of equivalent diameter and are
bilaterally symmetrical. (L,M) In Gbx2−/− embryos (n = 17), the 4th PAAs are frequently hypoplastic
(L) or non-patent to ink (M; asterisk). (N–S) Embryos were examined by high-resolution episcopic
microscopy at E10.5 (34–35 somites; N–P) and E11.5 (45–47 somites; Q–S). Coronal views are shown.
(N) In control E10.5 embryos (n = 5), the 3rd, 4th, and 6th PAAs, and the left and right dorsal aortae
(L/RdAo), are of equal size and bilaterally symmetrical. (O,P) In Gbx2−/− embryos (n = 3), the 4th
PAAs were either absent (O; asterisk), or hypoplastic (O,P). The left dorsal aorta was seen to be
abnormally thinner than the right (O,P). (Q) In control embryos at E11.5 (n = 3), the outflow tract is
septated into the aorta (A) and pulmonary trunk (pt), and the right 6th PAA has thinned. (R,S) In
Gbx2−/− embryos (n = 5), the 4th PAAs are frequently unilaterally absent (asterisk). Septation of the
aortic sac (as) is delayed. (T–V) Immunostaining using anti-ERG1 antibody at E10.5 (34–36 somites).
(T) Control embryos (n = 3) have a ring of ERG1-positive endothelium lining the 3rd and 4th PAAs
(white arrowheads). (U,V) In Gbx2−/− embryos (n = 4), the 4th PAAs appeared to have abnormal
endothelial cells (U), or disorganized endothelial cells within the 4th pharyngeal arch in the absence
of a PAA (V; yellow arrowheads). Scale bars: 500 µm in (A–H); 100 µm in (I–S); 50 µm in (T–V).
Abbreviations: Ao, aorta; AD, arterial duct; LCC, left common carotid artery; LSA, left subclavian
artery; LV, left ventricle; pa, pharyngeal arch; RCC, right common carotid artery; RSA, right subclavian
artery; RV, right ventricle; s, somites. The somite numbers given in the legend reflect the range analysed
for the whole study. The figure contains representative images only.
3.3. Genetic Interaction between Gbx2 and Pax9
To investigate a genetic interaction in vivo, mice heterozygous for Pax9 and Gbx2, which are viable
and fertile with no observed developmental defects, were intercrossed to produce Gbx2+/−;Pax9+/−
mice and embryos for analysis. Gbx2+/−;Pax9+/− mice were observed to survive to weaning albeit at a
significantly lower than expected number (p < 0.05; Table S2). To investigate any perinatal lethality to
explain the loss of Gbx2+/−;Pax9+/− mice, neonates were observed from the day of birth. Four pups were
recovered which had died on the first post-natal day, all of which were Gbx2+/−;Pax9+/−, and showed
a cardiovascular defect when dissected including RAA, IAA-B and A-RSA (Figure 3A–C; Table 1).
Surviving littermates were culled and a further eight Gbx2+/−;Pax9+/− neonates were identified which
showed no cardiovascular defects. All wild type (n = 8), Gbx2+/− (n = 10) and Pax9+/− (n = 9) littermates
were normal. To further investigate the Gbx2+/−;Pax9+/− cardiovascular phenotype, embryos were
collected at E15.5 and analysed by histology. From 16 Gbx2+/−;Pax9+/− embryos collected, two had a
defect affecting the arch arteries including RAA and A-RSA (Figure 3D–I) and RAD (Table 1). Embryos
were collected at E10.5 to analyse the forming PAA by ink injection. This revealed that 30% (n = 19/63)
of Gbx2+/−;Pax9+/− mutants had a defect where the 4th PAA was either hypoplastic or absent in affected
embryos (Figure 3J–L; Table 2).
J. Cardiovasc. Dev. Dis. 2020, 7, 20 10 of 24
J. Cardiovasc. Dev. Dis. 2020, 6, 10 of 24 
 
 
Figure 3. Cardiovascular defects in Gbx2+/–;Pax9+/– mice. (A–C) Neonates were dissected on the day of 
birth. (A) Arch arteries of control neonates were normal. (B) A subset of Gbx2+/–;Pax9+/– neonates (4/12) 
displayed right-sided aortic arch (RAA; B) or IAA-B (C). (D–I) H&E stained transverse sections of 
E15.5 embryos. (D–F) Normal outflow tract (D), aortic arch arteries and thymus (Th; E,F) in a control 
embryo. (G–I) A Gbx2+/–;Pax9+/– embryo (from n = 16) with aberrant right subclavian artery (A-RSA; 
G), a right-sided aortic arch (RAA; H) and abnormal thymus (H,I). (J–L) Intracardiac ink injection into 
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of E15.5 embryos. (D–F) Normal outflow tract (D), aortic arch arteries and thymus (Th; E,F) in a
control embryo. (G–I) A Gbx2+/−;Pax9+/− embryo (from n = 16) with aberrant right subclavian artery
(A-RSA; G), a right-sided aortic arch (RAA; H) and abnormal thymus (H,I). (J–L) Intracardiac ink
injection into E10.5 embryos (34–41 somites). (J) In control embryos, PAAs 3–6 are patent to ink, are of
equivalent diameter and are bilaterally symmetrical. (K,L) In Gbx2+/−;Pax9+/− embryos (n = 63), 32%
had hypoplastic (K) or non-patent to ink (L; asterisk) 4th PAAs. Scale bars: 1 mm in (A–C); 500 µm
in (D–L). Abbreviations: AD, arterial duct; Ao, aorta; AoA, aortic arch; LCC, left common carotid
artery; LSA, left subclavian artery; PT, pulmonary trunk; RCC, right common c roti artery; RSA, right
subclavian art ry; s, somi es. The somite numbers given in the legend reflect the range analysed for the
whole study. The figure contains representative images only.
Our data therefore indicates that there is a genetic interaction occurring between Gbx2 and Pax9,
albeit at a low incidence, where biallelic expression of both genes is required for cardiovascular
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development to proceed normally. There was a loss in the expected number of double heterozygous
mice at weaning and an observable aortic arch artery phenotype in a subset of embryos and neonates,
including IAA-B which was not seen in Gbx2−/− mice in this study (Table 1).
To see if a further reduction in Gbx2 and Pax9 alleles would result in a more penetrant cardiovascular
phenotype, Gbx2+/−;Pax9+/− mice were intercrossed and embryos and neonates collected for analysis.
Genotyping revealed that all mice null for Gbx2 were under-represented (p = 1.12 × 10−4; Table S3). We
first analysed mutant mice null for Gbx2 and simultaneously heterozygous for Pax9 (i.e., Gbx2−/−;Pax9+/−).
One Gbx2−/−;Pax9+/− neonate was recovered that died on the day of birth with IAA-B, A-RSA, and an
absent left common carotid artery resulting in the left internal and external carotid arteries arising
from the aortic arch and dorsal aorta as previously described in Pax9−/− embryos [25] (Figure 4A,B).
Gbx2−/−;Pax9+/− embryos at E13.5 and E15.5 were examined for cardiovascular defects by histology
and MRI respectively, which showed a significantly increased penetrance of OFT and arch artery
defects compared to those observed in Gbx2−/− mice (100% versus 64%, p < 0.05; Figure 4C–M; Table 1).
There was also a significant increase in the presentation of IAA-B in Gbx2−/−;Pax9+/− mice compared
to Gbx2−/− mice (36% versus 0, p < 0.01; Figure 4B,E; Table 1), a defect not observed in our Gbx2−/−
or Pax9+/− mice. We also observed a partial CAT (type A4 where the common trunk is associated
with IAA [44]) in one Gbx2−/−;Pax9+/− embryo (Figure 4G), a phenotype not previously described in
Gbx2-null and Pax9-null embryos [25,28,29]. Analysis of the PAA at E10.5 by ink injection revealed that
all Gbx2−/−;Pax9+/− embryos had an affected 4th PAA, with a significantly higher incidence of bilateral
4th PAA defects compared to Gbx2−/− embryos (p < 0.05; Figure 4N–Q; Table 2).
As Pax9 heterozygosity modified the Gbx2−/− phenotype we next looked to see if Gbx2
heterozygosity modified the Pax9−/− phenotype. Gbx2+/−;Pax9−/− embryos examined at E15.5 and
E10.5 presented with the typical Pax9-null cardiovascular phenotype (Figure 5) and no left-right
patterning defects were seen. Two cases of type A4 partial CAT, however, were observed (Figure 5I;
Table 1). At E10.5 there was an insignificant increase in the penetrance of 1st and 3rd PAA defects in
the Gbx2+/−;Pax9−/− embryos (Figure 5L; Table 2).
From the Gbx2+/−;Pax9+/− intercross only three Gbx2−/−;Pax9−/− mice were recovered from a total of
172 offspring, one each at P0, E15.5 and E10.5, and these mice displayed the typical Pax9−/− phenotypes,
as well as AVSD and full CAT (with an isolated right subclavian artery), both of which are defects not
previously seen in either Gbx2−/− or Pax9−/− embryos (Figure 6; Tables 1 and 2).
The thymus is always absent in Pax9−/− embryos [25], yet usually unaffected in Gbx2−/− embryos
(Figure S2; Table S4). In 70% of Gbx2−/−;Pax9+/− embryos the thymus was abnormal or absent. The palate,
however, was only affected in mice with Pax9−/− genotypes (Figure S2).
It appears, therefore, that creating complex alleles of Gbx2 and Pax9 reveals evidence of a genetic
interaction occurring between these two genes as cardiovascular defects are seen in double heterozygous
embryos. Furthermore, by creating more complex Gbx2;Pax9 alleles such as Pax9 heterozygosity with
the Gbx2−/− genotype and Gbx2 heterozygosity with the Pax9−/− genotype, not only are Pax9-null type
defects such as IAA-B and absent common carotid arteries introduced, but also a CAT phenotype not
seen in either single Gbx2−/− or Pax9−/− embryos is observed.
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carotid artery (iRC; F), and a partial common arterial trunk (pCAT) emerging from the left ventricle 
(G). The pulmonary trunk is right-sided (R-PT; H) and the aorta was interrupted (not shown). The 
thymus is absent in both mutants (F,H). (J–M) 3D reconstructions of MRI datasets of hearts from a 
normal control embryo (J) and Gbx2–/–;Pax9+/– mutant embryos (n = 8). Defects include aberrant right 
subclavian artery (A-RSA; K,L), double outlet right ventricle (DORV; K,M), right-sided aortic arch 
(RAA; L,M). Situs patterning defects were also observed, including mirror image aortic arch arteries 
(RAA, RAD, RdAo) with aberrant left subclavian artery (A-LSA) and aberrantly positioned ventricles 
(M). (N–Q) Intracardiac ink injection into E10.5 embryos (35–39 somites). (N) In control embryos, 
PAAs 3–6 are patent to ink. (K, L) In Gbx2+/–;Pax9+/– embryos (n = 7), all had an aberrant 4th PAA 
including hypoplastic (O) or non-patent to ink (P,Q; asterisk) vessels. Scale bars: 1 mm in A–B; 500 
µm in C–Q. Abbreviations: Ao, aorta; AD, arterial duct; dAo, dorsal aorta; LCC, left common carotid 
artery; LSA, left subclavian artery; LV, left ventricle; PT, pulmonary trunk; RCC, right common 
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Figure 4. Cardiovascular defects in Gbx2−/−;Pa +/− mice. (A–B) Neonates were dissected on the day of
birth. (A) Arch arteries of c ntrol neonates were normal. ( bx2−/−;Pax9+/− eonate found dead
on the day of birth displayed IA -B and an ab rr t left and right intern l and xternal carotid artery
(iLC, eLC, iRC, eRC). (C–H) H&E stained transverse sections of E13.5 embryos (n = 5). A normal outflow
tract (C), aortic arch (Ao) and thymus (Th; D) are seen in control embryos. In two Gbx2−/−;Pax9+/−
mutant embryos (E–H) the defects include IAA-B (E), an aberrant right internal carotid artery (iRC;
F), and a partial common arterial trunk (pCAT) emerging from the left ventricle (G). The pulmonary
trunk is right-sided (R-PT; H) and the aorta was interrupted (not shown). The thymus is absent in both
mutants (F,H). (J–M) 3D reconstructions of MRI datasets of hearts from a normal control embryo (J) and
Gbx2−/−;Pax9+/− mutant embryos (n = 8). Defects include aberrant right subclavian artery (A-RSA; K,L),
double outlet right ventricle (DORV; K,M), right-sid d aortic arch (RAA; L,M). Situs p tterning defects
were also observe , including mirror image ortic arch arteries (RAA, RAD, RdAo) with aberrant left
subclavian artery (A-LSA) a d ab rra tly positioned ventricles (M). (N–Q) Intracardiac ink injection
into E10.5 embryos (35–39 somites). (N) In control e bryos, PAAs 3–6 are patent to ink. (K,L) In
Gbx2+/−;Pax9+/− embryos (n = 7), all had an aberrant 4th PAA including hypoplastic (O) or non-patent
to ink (P,Q; asterisk) vessels. Scale bars: 1 mm in (A–B); 500 µm in (C–Q). Abbreviations: Ao, aorta;
AD, arterial duct; dAo, dorsal aorta; LCC, left common carotid artery; LSA, left subclavian artery; LV,
left ventricle; PT, pulmonary trunk; RCC, right common carotid artery; RSA, right subclavian artery;
RV, right ventricle; s, somites. The somite numbers given in the legend reflect the range analysed for
the whole study. The figure contains representative images only.
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birth. (A) Arch arteries of control neonates were normal. (B) Pax9–/– (n = 2) and (C) Gbx2–/–;Pax9+/– (n = 
2) neonates found dead on the day of birth displayed interruption of the aortic arch (IAA-B) and 
presumed aberrant right subclavian artery. (D–F) 3D reconstructions of E15.5 hearts from MRI 
datasets. (D) Gbx2+/+ control embryo with normal heart and aortic arch arteries. (E) Pax9–/– embryos (n 
= 7) presented with defects such as IAA-B, A-RSA, double outlet right ventricle (DORV), hypoplastic 
aorta and aberrant carotid arteries (eRCA, iRCA). (F) Gbx2+/–;Pax9–/– embryos (n = 7) showed typical 
Pax9–/– cardiovascular defects including IAA-B and absent common carotid artery, but also common 
Figure 5. Cardiovascular defects in Gbx2+/−; ax9−/− mice. (A–C) Neonates wer dissected on the day
of birth. (A) Arch arteries of c tr l e nates were normal. (B) Pax9−/− (n = 2) and (C) Gbx2−/−;Pax9+/−
(n = 2) neonates found dead on the day of birth displayed interruption of the aortic arch (IAA-B)
and presumed aberrant right subclavian artery. (D–F) 3D reconstructions of E15.5 hearts from MRI
datasets. (D) Gbx2+/+ control embryo with normal heart and aortic arch arteries. (E) Pax9−/− embryos
(n = 7) presented with defects such as IAA-B, A-RSA, double outlet right ventricle (DORV), hypoplastic
aorta and aberrant carotid arteries (eRCA, iRCA). (F) Gbx2+/−;Pax9−/− embryos (n = 7) showed typical
Pax9−/− cardiovascular defects including IAA-B and absent common carotid artery, but also common
arterial trunk (CAT). (G–I) E15.5 embryos were sectioned and stained with H&E. (G) Control embryos
had a normal outflow tract. (H) Pax9−/− embryos had DORV (not shown) and hypolastic aorta.
(I) Gbx2+/−;Pax9−/− embryo with CAT. (J–L) Embryos at E10.5 were analysed by intracardiac ink
injection (35–38 somites). (J) Control embryos had normal PAAs patent to ink. (K) Pax9−/− embryos
showed typical defects such as persistent 1st, hypoplastic 3rd and absent 4th PAAs (asterisk), as did
Gbx2+/−;Pax9−/− embryos (n = 6; L). Scale bars: 1 mm in (A–C); 500 µm in (D–L). Abbreviations: Ao,
aorta; AD, arterial duct; LCC, left common carotid artery; LSA, left subclavian artery; LV, left ventricle;
PA, pulmonary artery; PT, pulmonary trunk; RCC, right common carotid artery; RSA, right subclavian
artery; RV, right ventricle; s, somites. The somite numbers given in the legend reflect the range analysed
for the whole study. The figure contains representative images only.
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Figure 6. Cardiovascular defects in the three Gbx2–/–;Pax9–/– mutants recovered. (A–D) Neonates were 
dissected on the day of birth. The thymus (A) and arch arteries (B) were normal in controls, but in a 
Gbx2–/–;Pax9–/– neonate the thymus was absent (asterisk; C) and the arch arteries were abnormal (D) 
Figure 6. Cardiovascular defects in t t r e Gbx2−/−;Pax9−/− mutants r covered. (A–D) N onates
were cted on the day of birth. The thymus (A) and arch arteries (B) we e normal in controls, but in
a Gbx2−/−;Pax9−/− nate the thymus w s absent (a terisk; C) and t e arch art ies were bnormal
(D) displaying interrupted aortic arch type B (IAA-B), isolated right subclavian artery (I-RSA) and
abnormal left carotid arteries (eLCA, iLCA). (E,F) 3D reconstructions of E15.5 hearts from MRI datasets.
(E) Control embryo with normal heart and aortic arch arteries. (F) Gbx2−/−;Pax9−/− embryo with IAA-B,
I-RSA, common arterial trunk (CAT) with interventricular communication (IVC), and aberrant carotid
arteries (eLCA, iLCA, eRCA, iRCA). (G,H) Embryos at E10.5 were analysed by intracardiac ink injection.
(G) Control embryos had normal PAAs patent to ink. (H) Gbx2−/−;Pax9−/− embryo with a non-patent
4th PAA (asterisk). (I–P) H&E stained transverse sections of E15.5 embryos. (I–L) Control embryo with
normal heart (I), outflow tract (J), aortic arch arteries (K,L) and thymus (Th; L). (M–P) Sections from
the Gbx2−/−;Pax9−/− embryo depicted in F. (M) An atrioventricular septal defect (AVSD) is seen, as
well as the CAT (N) with associated I-RSA (O) and aberrant carotid arteries (P). Scale bars: 500 µm.
Abbreviations: AD, arterial duct; Ao, aorta; AoA, aortic arch; dAo, dorsal aorta; LA, left atrium; LCC,
left common carotid artery; LSA, left subclavian artery; LV, left ventricle; RA, right atrium; RCC, right
common carotid artery; RSA, right subclavian artery; RV, right ventricle.
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3.4. Gbx2 and Pax9 Interact in the Pharyngeal Endoderm for Cardiovascular Development
To further investigate the site of this genetic interaction we utilised our Pax9Cre mouse line, where
the Pax9Cre allele corresponds to a Pax9-null allele [25], to conditionally recombine the Gbx2flox allele
specifically in the pharyngeal endoderm (Figure S3). Embryos conditionally deleted for Gbx2 using
Pax9Cre (i.e., Gbx2−/flox;Pax9Cre) lost the majority of Gbx2 mRNA expression from the pharyngeal
endoderm at E9.5 (Figure 7B). Embryos at E10.5 were examined by ink injection to assess the PAAs.
Whereas only 10% (2/19) of embryos double heterozygous for Gbx2 in the pharyngeal endoderm
(i.e., Gbx2+/flox;Pax9Cre) had an abnormal 4th PAA (Table 2), there was a significant increase in the
penetrance of 4th PAA defects (7/14; p < 0.05) in the embryos null for Gbx2 in the pharyngeal endoderm
(i.e., Gbx2−/flox;Pax9Cre) (Figure 7D; Table 2). Examining Gbx2−/flox;Pax9Cre mutant mice at E15.5 by
MRI revealed cardiovascular defects including RAA, A-RSA and absent common carotid arteries in
3/14 embryos analysed (Figure 7F; Table 1). Despite a relatively low incidence of cardiovascular defects
in embryos with a conditional Pax9Cre driven deletion of Gbx2, this data collectively demonstrates that
a genetic interaction between Gbx2 and Pax9 is taking place in the pharyngeal endoderm.J. Cardiovasc. Dev. Dis. 2020, 6, 16 of 24 
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3.5. Exploring a Genetic Interaction between Gbx2, Pax9 and Tbx1 
Tbx1 has been shown to genetically interact with Gbx2 and Pax9 in the pharyngeal ectoderm and 
endoderm respectively [25,28]. Our and published data [42] also show that Pax9 and Tbx1 occupy the 
same conserved region in the Gbx2 locus (Figure 1) and Tbx1, Pax9 and Gbx2 are co-expressed in the 
pharyngeal endoderm at E9.5 and E10.5 (Figure 1C–F) [25,28]. Pax9 and Gbx2, and Tbx1 and Gbx2, 
are downregulated in the pharyngeal endoderm of Tbx1–/– and Pax9–/– mice respectively (Figure 8A–
L) [24,25] but Pax9 and Tbx1 expression were maintained in the pharyngeal endoderm of Gbx2–/– 
embryos at E9.5 (Figure 8D,H). We nevertheless speculated that a gene regulatory network may be 
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analysed Gbx2+/–;Pax9+/–;Tbx1+/– triple heterozygous embryos at E15.5-E16.5 by µCT imaging and 
compared the observed cardiovascular defects with double heterozygous Tbx1+/–;Pax9+/– and Tbx1+/–
;Gbx2+/– embryos (Figure 8M–R; Table 3). Although a non-significant reduction in the penetrance of 
4th PAA derived defects was seen in Tbx1+/–;Gbx2+/– embryos compared to Tbx1+/– embryos, a similar 
number and type of cardiovascular defect was observed between Tbx1+/–;Pax9+/– double heterozygous 
and Tbx1+/–;Gbx2+/–;Pax9+/– triple heterozygous embryos (Figure 8S,T). This suggests that there was no 
change to the Tbx1+/–;Pax9+/– 4th PAA-derived phenotype caused by haploinsufficiency of Gbx2. 
. i i l l i l . i ll
ll l and a heterozygous conditional deletion of Gbx2 using Pax9Cre (Gbx2−/flox;Pa 9Cre) were analysed.
(A,B) RNAscope in situ hybridisation for Gbx2 at E9.5 (n = 5 per genotype; 24–29 somites). (A) In control
embryos Gbx2 expression was observed in the pharyngeal endoderm (pe) of the pharyngeal arches
(pa). (B) Gbx2 expression was reduced in the pharyngeal endoderm of Gbx2−/flox;Pax9Cre mutants.
(C,D) Embryos at E10.5 were analysed by intracardiac ink injection (36–38 somites). (C) Control embryos
had normal PAAs patent to ink. (D) Gbx2−/flox;Pax9Cre embryos (n = 14) showed PAA defects such as
absent 4th PAAs (asterisk). (E,F) 3D reconstructions of E15.5 hearts from MRI datasets. (E) Control
embryo with normal heart and aortic arch arteries. (F) A Gbx2−/flox;Pax9Cre embryo (fr m n = 14
analysed) with double-outlet right ventricle (DORV), right-sided aortic arch (RAA), aberrant right
subclavian artery (A-RSA) and abnormal left external and internal carotid arteries (eLCA, iLCA). Scale
bars: 50 µm in (A,B); 100 µm in (C,D); 500 µm in (E,F). Abbreviations: Ao, aorta; AD, arterial duct; LCC,
left common carotid artery; LSA, left subclavian artery; LV, left ventricle; RCC, right common carotid
artery; RSA, right subclavian artery; RV, right ventricle; s, somite. The somite numbers given in the
legend reflect the range analysed for the whole study. The figure contains representative images only.
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3.5. Exploring a Genetic Interaction between Gbx2, Pax9 and Tbx1
Tbx1 has been shown to genetically interact with Gbx2 and Pax9 in the pharyngeal ectoderm and
endoderm respectively [25,28]. Our and published data [42] also show that Pax9 and Tbx1 occupy
the same conserved region in the Gbx2 locus (Figure 1) and Tbx1, Pax9 and Gbx2 are co-expressed
in the pharyngeal endoderm at E9.5 and E10.5 (Figure 1C–F) [25,28]. Pax9 and Gbx2, and Tbx1
and Gbx2, are downregulated in the pharyngeal endoderm of Tbx1−/− and Pax9−/− mice respectively
(Figure 8A–L) [24,25] but Pax9 and Tbx1 expression were maintained in the pharyngeal endoderm of
Gbx2−/− embryos at E9.5 (Figure 8D,H). We nevertheless speculated that a gene regulatory network
may be occurring in the pharyngeal endoderm involving Gbx2, Pax9 and Tbx1. To investigate this
we analysed Gbx2+/−;Pax9+/−;Tbx1+/− triple heterozygous embryos at E15.5-E16.5 by µCT imaging
and compared the observed cardiovascular defects with double heterozygous Tbx1+/−;Pax9+/− and
Tbx1+/−;Gbx2+/− embryos (Figure 8M–R; Table 3). Although a non-significant reduction in the penetrance
of 4th PAA derived defects was seen in Tbx1+/−;Gbx2+/− embryos compared to Tbx1+/− embryos, a similar
number and type of cardiovascular defect was observed between Tbx1+/−;Pax9+/− double heterozygous
and Tbx1+/−;Gbx2+/−;Pax9+/− triple heterozygous embryos (Figure 8S,T). This suggests that there was
no change to the Tbx1+/−;Pax9+/− 4th PAA-derived phenotype caused by haploinsufficiency of Gbx2.
Table 3. Number of cardiovascular defects observed in Tbx1;Gbx2;Pax9 mutant mice.
Genotype n VSD RAA +/orA-RSA
IAA-B +/−
A-RSA
4th PAA
Defect
Tbx1+/− a 21 2(10%)
13
(62%)
1
(5%)
14
(67%)
Tbx1+/−;
Pax9+/− b 24
5
(21%)
9
(38%)
15
(63%) **
24
(100%)
Tbx1+/−; Gbx2+/− 10 3(30%) 2(20%) 1(10%) 3(30%)
Tbx1+/−; Gbx2+/−; Pax9+/− 8 3(38%)
4
(50%)
4
(50%)
8
(100%)
Embryos were collected from Tbx1+/−;Gbx2+/− and Pax9+/− crosses. Embryos were analysed by µCT at E13.5-E16.5.
There was a statistically significant increase in the incidence of IAA-B in the Tbx1+/−;Pax9+/− embryos compared
with the Tbx1+/− embryos. ** p < 0.0001 (Pearson’s chi-squared test for associations with continuity correction).
a New data (n = 3) combined with published MRI data (n = 19) [25]. b New data (n = 4) combined with published
MRI data (n = 20) [25]. Abbreviations: A-RSA, aberrant right subclavian artery; IAA-B, interruption of the aortic
arch, type B; RAA, right-sided aortic arch; VSD, perimembranous ventricular septal defect.
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in control embryos. Pax9 expression is reduced in Tbx1–/– embryos (F), absent in Pax9–/– embryos (G), 
and present in Gbx2–/– embryos (H). (I) Gbx2 is expressed in the pharyngeal endoderm in control 
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aortic arch (RAA) and A-RSA. (Q, R) Tbx1+/–;Pax9+/–+/–;Gbx2+/– embryos with IAA-B and A-RSA. (S,T) 
Graphical representation of IAA-B incidence (S) and 4th pharyngeal arch artery (PAA) incidence (T) 
in Tbx1;Pax9;Gbx2 embryos. *p < 0.05; **p < 0.001; ***p < 0 0001; Pearson chi-squared test for 
Figure 8. Gbx2 heterozygosity does not modify the Tbx1;Pax9 double heterozygous phenotype.
(A–L) Tbx1, Pax9 and Gbx2 expression in E9.5–E10.5 control and Tbx1−/−, Pax9−/− and Gbx2−/− embryos
(n≥ 3 embryos per probe; 23–34 somites). (A) Tbx1 is expressed in the pharyngeal endoderm, mesoderm
and ectoderm in control embryos. Tbx1 expression is absent in Tbx1−/− embryos (B), reduced in Pax9−/−
embryos (C), and normal in Gbx2−/− embryos (D). (E) Pax9 is expressed in the pharyngeal endoderm
in control embryos. Pax9 expression is reduced in Tbx1−/− embryos (F), absent in Pax9−/− embryos
(G), and present in Gbx2−/− embryos (H). (I) Gbx2 is expressed in the pharyngeal endoderm in control
embryos. Gbx2 expression is reduced in Tbx1−/− ryos (J), reduced in Pax9−/− embryos (K), and
absent in Gbx2−/− ryos (L). (M–R) 3D reconstructions of E15.5–16.5 hearts from µCT datasets.
(M) Control embryo with normal heart and aortic arch arteries. (N) Tbx1+/− embryo with aberrant right
subclavian artery (A-RSA). ( ) /−;Pax9+/− embryo with interrupted ao tic arch type B (IAA-B)
and cervical or gin of the right subclavian artery (cRSA). (P) Tbx1+/−;Gbx2+/− embryo with a right-si ed
aortic arch (RAA) and A-RSA. (Q,R) Tbx1+/−;Pax9+/− /−;Gbx2+/− embryos with I A-B and A-RSA. (S,T)
Graphical repres ntation of IA -B incidence (S) and 4th pharyngeal arch artery ( ) i ci c ( ) in
Tbx1;Pax9;Gbx2 embryos. * p < 0.05; ** p < 0.001; *** p < 0.0001; Pearson chi-squared test for associations
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with continuity correction. Scale bars: 500 µm in M-R; 50 µm in (A–L). Abbreviations: Ao, aorta;
AD, arterial duct; LCC, left common carotid artery; LSA, left subclavian artery; LV, left ventricle; me,
mesoderm; pa, pharyngeal arch; pe, pharyngeal endoderm; p.ect, pharyngeal ectoderm; RCC, right
common carotid artery; RSA, right subclavian artery; RV, right ventricle; s, somite. The somite numbers
given in the legend reflect the range analysed for the whole study. The figure contains representative
images only.
4. Discussion
In this study, we have employed imaging and gene interaction methodologies to provide an
in-depth analysis of the Gbx2 mutant cardiovascular phenotype throughout embryogenesis and
demonstrate a genetic interaction with Pax9 in the pharyngeal endoderm.
4.1. Gbx2-Null Mice
Our analysis of the Gbx2-null cardiovascular phenotype revealed differences from two previously
published papers. At mid-embryogenesis we found 71% of mutants had an abnormal 4th PAA,
compared to 50% previously reported [28], and at foetal stages, we identified 64% of mutants had a
cardiovascular defect, although none displayed IAA, compared to 39% previously reported where IAA
was included [29]. One explanation for the cardiovascular phenotype discrepancy between studies is
the Gbx2-null allele used. In the previously published studies, the neomycin selection cassette was
retained in the first intron of Gbx2 [32,41], whereas it was removed from the allele used in our study.
It is possible that the presence or absence of the neomycin cassette, which has been described to alter
mutant mouse phenotypes [45], may have influenced the presentation of the cardiovascular phenotype.
Alternatively, some cardiovascular defects may have been overlooked in the previous reports, or a
subtle change in genetic background may influence the presentation of phenotypes.
The cardiovascular structures predominantly affected in Gbx2-null embryos were the OFT, with
DORV seen in 40% of mutants, and the 4th PAA-derived vessels, with 50% of mutants having an
aberrant subclavian artery which was either retro-oesphageal or isolated. Although the formation of
the 4th PAA was more frequently observed to be affected at mid-embryogenesis in Gbx2-null embryos,
with this vessel seen to be absent or hypoplastic in 71% of mutants, this did not translate into an
IAA-B phenotype at the foetal stage as would be expected if the left 4th PAA had failed to form.
Immunolabelling of Gbx2−/− embryos showed a disorganisation of the endothelial cells within the
4th pharyngeal arch indicating that the 4th PAA fails to lumenise. This has also been previously
described in Gbx2−/− embryos [29], as well as in other mouse models where the failure of the 4th PAA
is a feature, for example, in Pax9−/− [25] and Tbx1 mutant [28] embryos. The discrepancy in 4th PAA
defects observed at an earlier developmental stage, yet not manifesting into a defect at a later stage, is
a well-known phenomenon observed in Tbx1+/− embryos [25,28,46–49]. The recovery of the left 4th
PAA may explain why we did not observe IAA-B in the Gbx2-null embryos.
Patients that present with an incomplete reversal of the internal organs are diagnosed with
heterotaxy which refers to any defect of left-right patterning and arrangement of the visceral organs.
We identified previously unreported left-right patterning defects in a third of all Gbx2-null mutants
examined. We did not find any change in Pitx2c expression in the left lateral plate mesoderm in
Gbx2-null embryos at E8.5, although we did not pre-select embryos for in situ hybridisation analysis
based on any morphological abnormalities such as the orientation of the OFT. Gbx2 may function
in left-right patterning independently of Pitx2c. Left-right patterning defects are largely a result of
abnormalities at the node of the primitive streak from E7.0 [50] and Gbx2 is expressed in all three
germ layers at gastrulation in the posterior epiblast [30], a region encompassing the node. Overall, the
number of Gbx2−/− embryos obtained was significantly lower than expected showing that more than
half of Gbx2−/− embryos are lost prior to E8.5 in early embryogenesis, regardless of the accompanying
Pax9 genotype. Early Gbx2 expression could, therefore, be critical for gastrulation and some embryos
lacking Gbx2 may not proceed through development at this stage. The surviving embryos may then
go on to develop left-right patterning and cardiovascular defects. Alternatively, Gbx2 may function
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downstream of Pitx2c to regulate the asymmetric development of the internal organs. Pitx2 is a
regulator of gene expression [51] and the Pitx2c isoform plays an important role in the final stages of
organ asymmetry [52] including aortic arch and outflow tract development [53,54]. Pitx2c mutant mice
have OFT defects due to abnormal proliferation within the OFT myocardium [55]. Gbx2 may, therefore,
be a downstream target of Pitx2c and further work is required to investigate this possibility.
4.2. Genetic Interaction with Pax9
Mice double heterozygous for Gbx2 and Pax9 were under-represented at weaning, and some
were found to die at birth with cardiovascular defects. These data indicate there is a genetic
interaction between Pax9 and Gbx2 in cardiovascular development. Interestingly, the RAA and IAA-B
phenotypes observed in Gbx2+/−;Pax9+/− neonates are commonly seen in Gbx2−/− and Pax9−/− mice
respectively [25,29] but not in single heterozygous mice for these genes. When Gbx2−/− mice were
also heterozygous for Pax9 (i.e., Gbx2−/−;Pax9+/−), 100% of embryos and neonates presented with a
cardiovascular defect (significantly increased when compared to 64% of Gbx2−/− mice), including
left-right patterning defects, and there was a significantly increased incidence of IAA-B. Moreover,
CAT was observed, a phenotype not previously identified in Gbx2−/− or Pax9−/− mice [25,29]. When
we produced embryos null for Pax9 and heterozygous for Gbx2 (i.e., Gbx2+/−;Pax9−/−), or double
knockouts, they all presented with typical Pax9-null defects but also additionally displayed CAT or
AVSD. Embryos with a Pax9−/− genotype, however, did not display a left-right patterning defect as
seen in the Gbx2−/− mice. Our data suggest that a reduction in bi-allelic Gbx2 and Pax9 expression leads
to a modification of the phenotypes typically seen in the single-gene knockout mice.
The cardiovascular defects observed in the Gbx2;Pax9 mutant mice such as AVSD, CAT and
DORV are reminiscent of abnormal SHF development. Two-thirds of patients with heterotaxy have
AVSD [56] and this defect arises from the failure of the SHF-derived dorsal mesenchymal protrusion
to complete atrioventricular septation [57]. Patients with 22q11DS, where hemizygous expression of
TBX1 underlies the observed cardiovascular defects, may present with CAT [58], and this phenotype
is fully penetrant in Tbx1-null mice [34,59]. Tbx1 is expressed in the SHF [60], which overlaps with
the pharyngeal endoderm [61], where Pax9 and Gbx2 are also expressed. It is therefore feasible that
the pharyngeal endoderm expression of Pax9 and Gbx2 are influencing the formation of SHF-derived
cardiovascular structures. There could also be a defective contribution in the Gbx2;Pax9 mutant mice
from neural crest cells (NCC) migrating through the pharyngeal arches and into the OFT where they
participate in septation [8]. Mouse models with NCC defects often present with CAT [62,63]. It has
been reported that a reduced number of NCC are present within the caudal pharyngeal arches in
Pax9-null embryos at E10.5 [25] and Gbx2-null mice show aberrant migration of NCC [28,29]. A NCC
defect, combined with deficiencies in the pharyngeal endoderm component of the SHF, could, therefore,
become more penetrant on a Gbx2;Pax9 mutant background resulting in a higher incidence of the CAT
and IAA-B phenotypes [64].
4.3. Gbx2 and Pax9 Interact in the Pharyngeal Endoderm
Cardiovascular defects were observed when Gbx2 was conditionally deleted from the developing
embryo using the Pax9Cre allele, and these were at a comparable level to that observed in the constitutive
double heterozygous embryos, although the IAA-B phenotype was not seen. A higher incidence
of 4th PAA defects, however, was seen in the conditional mutants at E10.5 when analysed by ink
injection compared to those observed at foetal stages. As discussed above, it is well recognised that the
4th PAA can recover during development and there is not always a direct correlation to defects that
are subsequently seen at the foetal stages. At the E10.5 stage, half the conditional Gbx2−/flox;Pax9Cre
embryos presented with 4th PAA defects, whereas 100% of the constitutive Gbx2−/−;Pax9+/− embryos
did, suggesting that either 4th PAA morphogenesis is only partly controlled from the pharyngeal
endoderm or the Cre-mediated recombination of the Gbx2-floxed allele is not 100% efficient. Residual
expression of Gbx2 RNA was observed in the pharyngeal endoderm of Gbx2−/flox;Pax9Cre embryos
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(Figure 7B), which may be due to the concomitant onset of Pax9Cre and Gbx2 expression at E8.5
resulting in a slight delay in Cre activity on the Gbx2-floxed allele. It has previously been shown that
the deletion of Gbx2 from the pharyngeal ectoderm using AP2αCre mice resulted in a 47% penetrance of
4th PAA defects at E10.5 with the distribution of unilateral and bilateral 4th PAA defects in conditional
endoderm and ectoderm mutants being very similar [28]. It is therefore tempting to speculate that
Gbx2 expression from both pharyngeal epithelial tissues is required for correct 4th PAA morphogenesis.
The incidence of defects seen at foetal and embryonic stages in the constitutive Gbx2−/−, Pax9−/− and
Gbx2;Pax9 complex mutants was fairly concordant indicating that 4th PAA defects observed at E10.5 in
these genotypes did proceed directly to arch artery defects at foetal stages.
4.4. The Tbx1;Pax9 Double Heterozygous Phenotype is not Modulated by Gbx2 Haploinsufficiency
Mice heterozygous for Tbx1 typically have defects affecting the 4th PAA such as IAA and
A-RSA [65], but have also been shown to present with further cardiac defects such as VSD [59,66].
Tbx1 has been shown to genetically interact with Pax9 and Gbx2 in the pharyngeal endoderm and
ectoderm, respectively [25,28]. We identified three PAX binding sites in a highly conserved region of
the GBX2 locus, as well as a previously validated TBX binding site [42]. In luciferase assays, PAX9 was
able to activate the Gbx2 conserved region although TBX1 did not, and when PAX9 and TBX1 were
co-expressed, PAX9 was not able to activate the reporter. This suggests that PAX9 can activate Gbx2
through binding to the conserved region, whereas TBX1 acts as a repressor. However, to fully provide
conclusive evidence for a molecular interaction for Gbx2 expression to be driven by Pax9 or Tbx1,
further experiments would need to be performed such as an electromobility shift assay or chromatin
immunoprecipitation experiments. Mutating the putative binding sites in the luciferase assay would
also determine specificity. Gene expression is highly dynamic during cardiovascular development with
constant switching between gene activation and suppression [67]. For example, Tbx1 acts as a poised
enhancer to bind and keep DNA in the open state to then recruit other transcription or regulatory
factors. It has been shown that Tbx1 recruits P53 to Gbx2 to modulate Gbx2 expression through histone
methylation [42]. As Tbx1 also regulates histone modification [68] it could have a potential role in
controlling the timely activation of Gbx2 by Pax9 during cardiovascular development.
Tbx1, Pax9 and Gbx2 are all expressed in the pharyngeal endoderm at E9.5 and E10.5, and could,
therefore, function together in the endoderm which is acting as a signalling centre to interact with
other tissue types required in PAA morphogenesis. Pax9 and Tbx1 were each downregulated in
Tbx1−/− and Pax9−/− embryos respectively, which suggests that Tbx1 and Pax9 act in a non-hierarchal
pathway [25]. Tbx1 and Pax9 expression in Gbx2−/− embryos, however, were unaffected indicating
that these genes function hierarchically upstream of Gbx2. This is reflected in our phenotyping
data where we did not identify any difference in the incidence of 4th PAA-derived defects at foetal
stages in Tbx1+/−; Pax9+/−;Gbx2+/− triple heterozygous mutants compared to Tbx1+/−; Pax9+/− double
heterozygous mutants. Of note, however, in our study we only identified a low penetrance of 4th
PAA-derived defects in Tbx1+/−;Gbx2+/− mutants, and only one incidence (10%) of IAA-B. This is in
contrast to that previously shown for embryos of the same genotype where 27% of mutants (6 out of
22) had IAA-B [28]. This could possibly be attributed to the use of a different Gbx2 targeted allele as
discussed above.
5. Conclusions
In summary, a genetic regulatory network comprising of Tbx1, Pax9 and Gbx2 is required to control
morphogenesis of the arch arteries and the outflow tract of the developing cardiovascular system, and
this interaction occurs, in part, within the pharyngeal epithelia at mid-embryogenesis in the mouse.
An earlier role for Gbx2 in establishing left-right patterning requires further investigation.
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